The committees will meet to discuss the pediatric-focused safety review for OxyContin (oxycodone hydrochloride) extended-release tablets, as mandated by the Food and Drug Administration Safety and Innovation Act (Pub. L. 112-144), and to discuss pediatric data considerations for opioid analgesics labeling and Pediatric Research Equity Act studies for opioids generally, using Opana IR as an example.
Back to All Events
Earlier Event: September 18Nonprescription Drugs Advisory Committee
Later Event: September 27Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee